Company: OSRH
Filing Date: 2025-01-24
Form Type: S-4/A
Source: 0001213900-25-006139
Chunk: 392

Company: OSR Holdings, Inc.
Filing Date: 2025-01-24
Form: S-4/A
Chunk 392
---
           |     | VXM01 – combination (5)                                                                       
 WO 2016/202459, VEGFR-2 targeting DNA vaccine for combination therapy                         |     | Owned             |     | Composition of Matter; Method of Use |     | AU, CA, CN, EP, IN, US, ZA         |     |       2036 |
|           |     | VXM01 Tumor expression (7)                                                                    
 WO 2018/149982, Novel VEGFR-2 targeting immunotherapy approach                                |     | Owned             |     | Composition of Matter                |     | AU, US                             |     |       2038 |
| Darnatein |     | Designer ligands of TGF-ß superfamily (0)                                                     
 WO 2010/099219                                                                                |     | Exclusive License |     | Composition of Matter                |     | EP, KR, JP                         |     |       2030 |

Individual patents are in force for varying periods of time, depending upon the date of filing of the patent application, the date of patent issuance, and the legal term of patents in the countries in which they are obtained. Generally, patents issued for applications filed in the United States are in force for 20 years from the earliest nonprovisional filing date. In addition, in certain instances, a patent term can be adjusted or extended to recapture a portion of the term effectively lost as a result of the USPTO delay or the FDA regulatory review period (a patent term adjustment or patent term extension, respectively). The restoration period for FDA delay cannot be longer than five years and the total patent term, including the restoration period, must not exceed 14 years following FDA approval. The duration of patents outside of the United States varies in accordance with provisions of applicable local law, but typically is also 20 years from the earliest nonprovisional filing date. However, the actual protection afforded by a patent varies on a product -by-productbasis, from country -to-country, and depends upon many factors, including the type of patent, the scope of its coverage, the availability of regulatory -relatedextensions, the availability of legal remedies in a particular country, and the validity and enforceability of the patent. When appropriate, we seek to protect aspects of our technology and business not amenable to, or that we do not consider appropriate for, patent protection as trade secrets. We seek to protect this intellectual property, in part, as trade secrets, by entering